KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Research & Development (2016 - 2025)

Historic Research & Development for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Q3 2025 value amounting to $87.8 million.

  • Acadia Pharmaceuticals' Research & Development rose 3186.35% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.8 million, marking a year-over-year increase of 2804.62%. This contributed to the annual value of $303.2 million for FY2024, which is 1375.64% down from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Research & Development stood at $87.8 million for Q3 2025, which was up 3186.35% from $78.0 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Research & Development ranged from a high of $157.0 million in Q3 2023 and a low of $56.9 million during Q2 2021
  • Its 5-year average for Research & Development is $78.9 million, with a median of $75.6 million in 2022.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Research & Development soared by 12616.85% in 2022 and then crashed by 5756.58% in 2024.
  • Acadia Pharmaceuticals' Research & Development (Quarter) stood at $66.9 million in 2021, then increased by 13.14% to $75.7 million in 2022, then fell by 11.88% to $66.7 million in 2023, then surged by 50.93% to $100.7 million in 2024, then decreased by 12.81% to $87.8 million in 2025.
  • Its last three reported values are $87.8 million in Q3 2025, $78.0 million for Q2 2025, and $78.3 million during Q1 2025.